|
| Status |
Public on Dec 06, 2007 |
| Title |
MPM002214 |
| Sample type |
RNA |
| |
|
| Source name |
tumor sample
|
| Organism |
Homo sapiens |
| Characteristics |
studyCode = 40
treatment = PS341
sex = Male
race = White
Age_at_Randomization = 39
Date_of_Randomization = 26-Nov-02
Myeloma_Measure = IGA
PGx_Response = PR
PGx_Responder = R
PGx_Progression(0=No,1=Yes) = 1
PGx_Days_To_Progression = 204
Did_Patient_Die(0=No,1=Yes) = 1
Days_Survived_From_Randomization = 344
albumin = 34
Number_of_Prior_Lines = 4
meanMyelScore = 19.36
TC_Class_2006 = 4p16
|
| Treatment protocol |
samples were subject to a rapid enrichment procedure (see details in http://bloodjournal.hematologylibrary.org/cgi/content/full/109/8/3177) and tumor cell pellet was frozen
|
| Growth protocol |
tumor samples were collected during patient screening period prior to entry into clinical trials for the treatment of multiple myeloma
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNA was isolated using Qiagen RNAeasy kit
|
| Label |
biotin
|
| Label protocol |
A standard T7 based amplification protocol (Affymetrix) was used to convert 2.0 microgram of RNA to biotinylated cRNA.
|
| |
|
| Hybridization protocol |
cRNA for each sample was hybridized in triplicate to the U133A/B array. Data represent median of replicates that passed array QC.
|
| Scan protocol |
Microarrays were scanned with GeneArray 3000 scaner (Affymetrix).
|
| Description |
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
|
| Data processing |
Dataprocessing used Affymetrix MAS5.0.
|
| |
|
| Submission date |
Dec 04, 2007 |
| Last update date |
Dec 05, 2007 |
| Contact name |
George Mulligan |
| Organization name |
Millennium Pharmaceuticals
|
| Department |
Clinical Development
|
| Street address |
35 Landsdowne Stree
|
| City |
Cambridge |
| State/province |
MA |
| ZIP/Postal code |
02139 |
| Country |
USA |
| |
|
| Platform ID |
GPL97 |
| Series (1) |
| GSE9782 |
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib |
|
